Tag: HER2-negative
Oxford Bio Receives US Investigational New Drug Clearance for OBT076
The U.S Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for OBT076, an experimental antibody-drug conjugate or ADC being developed...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
